(S)-Zanubrutinib
CAS No. 1691249-45-2
(S)-Zanubrutinib ( S)-Zanubrutinib | BGB3111 | BGB 3111 )
产品货号. M12579 CAS No. 1691249-45-2
(S)-Zanubrutinib (BGB3111) 是一种有效的、选择性的、口服的 Btk 抑制剂。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 2MG | ¥820 | 有现货 |
|
| 5MG | ¥1349 | 有现货 |
|
| 10MG | ¥2432 | 有现货 |
|
| 25MG | ¥3980 | 有现货 |
|
| 50MG | ¥5701 | 有现货 |
|
| 100MG | ¥7605 | 有现货 |
|
| 500MG | ¥15210 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
| 1 mL x 10 mM in DMSO | ¥1074 | 有现货 |
|
生物学信息
-
产品名称(S)-Zanubrutinib
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述(S)-Zanubrutinib (BGB3111) 是一种有效的、选择性的、口服的 Btk 抑制剂。
-
产品描述(S)-Zanubrutinib (BGB3111)?is a potent, selective and orally available Btk inhibitor; shows much more restricted off-target activities against a panel of kinases, including ITK, compared with Ibrutinib; demonstrates nanomolar BTK inhibition activity, inhibits BCR aggregation-triggered BTK autophosphorylation, blocks downstream PLC-γ2 signaling, and potently inhibits cell proliferation in several MCL and DLBCL cell lines; demonstrates better anti-tumor activity than ibrutinib in TMD-8 subcutaneous xenograft model.
-
体外实验——
-
体内实验——
-
同义词S)-Zanubrutinib | BGB3111 | BGB 3111
-
通路Tyrosine Kinase
-
靶点BTK
-
受体BTK
-
研究领域Cancer
-
适应症——
化学信息
-
CAS Number1691249-45-2
-
分子量471.561
-
分子式C27H29N5O3
-
纯度>98% (HPLC)
-
溶解度DMSO : ≥ 56.75 mg/mL 120.35 mM; Ethanol : < 1 mg/mL
-
SMILESC=CC(=O)N1CCC(CC1)C2CCNC3=C(C(=NN23)C4=CC=C(C=C4)OC5=CC=CC=C5)C(=O)N
-
化学全称(7S)-4,5,6,7-Tetrahydro-7-[1-(1-oxo-2-propen-1-yl)-4-piperidinyl]-2-(4-phenoxyphenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Na Li, et al. Abstract 2597: BGB-3111 is a novel and highly selective Bruton's tyrosine kinase (BTK) inhibitor. AACR.
021-51111890
购物车()
sales@molnova.cn

